Circ‐102,166 is downregulated in HCC patients and can sponge miR‐182 expression and reduce the cell growth, migration, invasion, and tumorigenicity of HCC by upregulating the miR‐182 targets’ MTSS1 and FOXO3a [42]. Here, FOXO3 is linked to hepatocellular carcinoma.